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A Conformation Selective Mode of Inhibiting SRC
Improves Drug Efficacy and Tolerability
Carolin Temps1, Daniel Lietha2, Emily R. Webb1, Xue-Feng Li3, John C. Dawson1, Morwenna Muir1,
Kenneth G. Macleod1, Teresa Valero1, Alison F. Munro1, Rafael Contreras-Montoya1,
Juan R. Luque-Ortega2, Craig Fraser1, Henry Beetham1, Christina Schoenherr1, Maria Lopalco4,




Despite the approval of several multikinase inhibitors that
target SRC and the overwhelming evidence of the role of SRC in
the progression and resistance mechanisms of many solid malig-
nancies, inhibition of its kinase activity has thus far failed to
improve patient outcomes. Here we report the small molecule
eCF506 locks SRC in its native inactive conformation, thereby
inhibiting both enzymatic and scaffolding functions that prevent
phosphorylation and complex formation with its partner FAK.
This mechanism of action resulted in highly potent and selective
pathway inhibition in culture and in vivo. Treatment with
eCF506 resulted in increased antitumor efficacy and tolerability
in syngeneic murine cancer models, demonstrating significant
therapeutic advantages over existing SRC/ABL inhibitors. There-
fore, this mode of inhibiting SRC could lead to improved
treatment of SRC-associated disorders.
Significance: Small molecule–mediated inhibition of SRC
impairing both catalytic and scaffolding functions confers increased
anticancer properties and tolerability compared with other
SRC/ABL inhibitors.
Introduction
The SRC kinase, product of the first cellular proto-oncogene
identified (1–6), emerged as a potential therapeutic target in the early
1980s (7). Althoughdecades of research have assisted in elucidating the
central role of this nonreceptor tyrosine kinase in the transduction of
multiple oncogenic signals, either via receptor tyrosine kinases, cell-to-
cell or extracellular matrix-to-cell communications (7–12), accumu-
lating evidence of additional roles for SRC in cancer keeps it in the
spotlight (13–16). Predominantly inactive in noncancerous cells, SRC
is aberrantly activated in many cancer types, including breast, colon,
prostate, pancreatic, and ovarian cancers (17). With few excep-
tions (18), increased SRC activity is generally associated with late-
stage cancers, metastatic potential, and resistance to therapies, and
correlates with poor clinical prognosis (19–21). Surprisingly, despite
the vast amount of evidence gathered over the years and the approval of
dual SRC/ABL kinase inhibitors to treat BCR-ABL-positive leuke-
mias (22), to date no kinase inhibitor has yet been approved for the
treatment of SRC-active solid malignancies.
Because of high structural similarities between their active
sites (23), most small molecule inhibitors targeting SRC family
kinases—including the clinical drugs dasatinib and bosutinib—
display equal potency against the nonreceptor tyrosine kinase ABL.
Although dual inhibition of ABL and SRC can be beneficial in the
treatment of hematologic cancers (24), this polypharmacologic
profile is not desirable to treat other tumors, as several studies
have found that ABL kinase can act as a tumor suppressor in
different malignancies (25–31). Moreover, ABL regulates cardio-
myocyte growth and development (32), and its inhibition is directly
linked to cardiotoxic events (33, 34) and immunosuppression (35)
in patients with leukemia, which makes unwanted ABL inhibition a
clinical liability.
The novel SRC inhibitor eCF506 (Fig. 1A) displays subnanomolar
activity against SRC (36), a potency that is on par with the current best-
in-class SRC/ABL inhibitor dasatinib (37). In contrast, eCF506
requires concentrations three orders of magnitude greater to inhibit
ABL, which differentiates it from existing SRC/ABL inhibitors. As the
reasons behind this selectivity could be beneficial for the treatment of
SRC-associated pathologies, we set to investigate the mode of binding
of eCF506 to SRC and the molecular phenotype of eCF506-treated
breast cancer cells comparedwith clinical SRC/ABL inhibitors. Herein,
we report compelling structural and mechanistic data that defines the
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mode of SRC inhibition by eCF506, which provides explanation to the
selectivity and potency of this promising drug candidate. Using
syngeneic models of breast cancer and bone metastasis, we also show
that the unique properties of eCF506 translates into increased anti-
tumor efficacy and tolerability.
Materials and Methods
Chemicals
eCF506 was synthesized in five steps from commercially available
starting materials following the procedure previously reported (36).
Dasatinib was acquired from Cell Guidance Systems (SM45). Bosu-
tinib (S1014), saracatinib (S1006), and imatinib (S2475) were pur-
chased from Selleck Chemicals. Citrate buffer preparation: 18 mL of
0.1M citric acid (21 g in 1 L water), 82 mL of 0.1 sodium citrate (29.4 g
in 1 L water), make up to 1 L with water.
Cell lines
Cell lines were purchased from the European Collection of Authen-
ticated Cell Cultures (MDA-MB-231 and MCF7) or were a kind
donation from the cell bank of the Institute of Genetics and Cancer,
Edinburgh. MetBo2 cells were established in Dr. Qian’s lab. Cell lines
in culture were tested for mycoplasma every 2 months and authen-
ticated by STR profiling. Cells (at passage 10 or below) were grown in
their specific culture medium (see Supplementary Materials and
Methods) and maintained in a Heracell 240i tissue culture incubator
(37C, humidified air, 5% CO2).
Coimmunoprecipitation
Cells were seeded in 10 cm dishes, left to attach overnight and
treated with compounds for 6 hours (3 hours for FAK-IP) prior to lysis
with RIPA buffer. Protein concentration was determined using a BCA
assay and 1 mg/mL samples were prepared in a microcentrifuge tube,
to which, 20 mL Dynabeads Magnetic Beads Protein A (Invitrogen,
10002D) were added. Twomicrograms of primary SRC antibody (Cell
Signaling Technology, 2109) or appropriate IgG control (Cell Signal-
ing Technology, 2729) was added, and samples rotated at 4C over-
night. Dynabeads were washed twice with RIPA lysis buffer and
three times with PBS before being resuspended in 20 mL of 1
Laemmli sample buffer. Samples were heated to 95C for 5 minutes
and beads were separated using the magnetic rack before lysates
were analyzed for SRC (SCB, SC-8056) and FAK (Cell Signaling
Technology, 3285) by standard Western blot analysis. For the FAK-
IP 1 mg of cell lysate was incubated with anti-FAK (clone 4.47)–
conjugated agarose antibody (Millipore, 5–537). The agarose beads
were washed twice with RIPA buffer and twice with PBS before
being resuspended in 20 mL of 1 Laemmli sample buffer. Samples
were heated to 95C for 5 minutes and analyzed for SRC (Cell
Signaling Technology, 2109) and FAK (Cell Signaling Technology,
















A, Chemical structure of eCF506. B, Structure of eCF506 bound to the inactive conformation of the SRC kinase domain (DFG in, C-helix out). Amino
acid numbering corresponds to human SRC. C, Superimposed structures of autoinhibited SRC kinase (PDB 2SRC) and co-crystal structures SRC:eCF506
(PDB 7NG7) and SRC:dasatinib (PDB 3G5D). The orientation of the C-helix is highlighted.
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Cell proliferation assays
Cells were seeded in 96-well plates, with edge wells being filled
with PBS instead. After 48 hours, the medium was removed and
95 mL of fresh medium was added. Dilution plates of the test
compounds were prepared in DMSO and diluted 1:50 into medium,
of which, 5 mL were added to the cell plates (final DMSO concen-
tration 0.1% v/v). Cells were treated for 5 days before cell viability
was measured using PrestoBlue (Invitrogen). PrestoBlue was added
to an untreated plate on day 2 and to the treated plates on day 7 (1 in
10 dilution) and fluorescence (550 nm excitation, 580 nm emission)
was measured after the same incubation time on both days (0.25–
6 hours after addition, depending on cell line) using a Perkin Elmer
Envision 2101 plate reader. The average fluorescence on day 2 was
subtracted from the values on day 7 to distinguish between cyto-
toxic and cytostatic treatment effects and the data were normalized
to DMSO controls. GraphPad Prism 7 was used to fit nonlinear
regression curves and determine the concentration for 50% growth
inhibition (GI50).
Western blotting
Cells were seeded in 6-well plates and incubated for 48 hours
until approximately 70% confluence was reached. Compounds were
added (final DMSO concentration 0.1% v/v) and cells incubated for
the time specified (3 or 24 hours). Plates were put on ice, the
medium was removed, and cells were washed twice with ice-cold
PBS. RIPA lysis buffer with protease and phosphatase inhibitors
was added (1.25 mmol/L PMSF, 0.1% v/v aprotinin, 100 mmol/L
Na3VO4, 500 mmol/L NaF) and the cells were scraped, collected,
and incubated on ice for 10 minutes with occasional vortexing.
Lysates were centrifuged at 4C (17,000  g, 10 min) and the
supernatant was transferred into a new microcentrifuge tube. The
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225)
was used to determine the protein concentration according to the
manufacturer’s instructions, with samples being diluted one in four
and set up in duplicate on 96-well plates. Plates were read on a
Spark 20M microplate reader (Tecan) and absorbance was mea-
sured at 562 nm. Samples for SDS-PAGE were prepared as
follows: 20 mg protein was diluted with RIPA buffer to a final
volume of 15 mL, to which, 5 mL of 4X Laemmli Sample Buffer (Bio-
Rad, 1610747) were added. Samples were heated to 95C for 5
minutes and then loaded onto 12-well 4–15% Mini-PROTEAN
TGX precast gels (Bio-Rad, 4561045). Precision Plus Protein Dual
Color Standards (Bio-Rad, 1610374) were loaded alongside the
lysates. Gels were run in Mini-PROTEAN Tetra Cell tanks in TGS
buffer (pH 8.3) at 150 V for 45 minutes. Proteins were transferred
onto Trans-Blot Turbo Nitrocellulose membranes (Bio-Rad,
1704159) using the Trans-Blot Turbo Transfer System (Bio-Rad)
for semi-dry blotting at 2.5 A (midi) or 1.3 A (mini) and up to 25 V
for 10 minutes. Membranes were cut and blocked with blocking
buffer (TBST 0.1% with 5% w/v BSA) for 1 hour at room temper-
ature before incubation with primary antibodies at 4C overnight.
Membranes were washed twice with TBST (0.1%) for 3 minutes
before addition of secondary antibodies and incubation for 2 hours
at room temperature, before washing another three times with
TBST (0.1%) for 5 minutes. Antibodies were detected by chemilu-
minescence by incubating membranes for 2 minutes with the
Clarity ECL Western Blotting Substrates (Bio-Rad, 102031309)
before imaging in the ChemiDoc XRSþ Imaging System (Bio-Rad).
Protein bands were quantified using the ImageLab software v5.2
(Bio-Rad) with automated band detection and background sub-
traction (disk size 70 mm).
Animal experiments
Animal experiments were performed under HomeOffice License in
compliance with the Animals (Scientific Procedures) Act 1986 and
approved by the University of Edinburgh Ethics Committee.
Bone metastasis model
FVB/NHanHSD (FVB) mice were anesthetized by isoflurane and
injected with 100,000 MetBo2 cells into the left ventricle. Tumor
growth was monitored by bioluminescence imaging on the Optima
imager (Biospace). Bone metastasis tumors were allowed to grow for
7 days until the signals of bone metastasis were clearly detected by
Optima imager. Eleven mice that developed tumors in the hind legs or
jaw were included in the study. Mice were randomized and put into
control (5 mice) or treatment (6 mice) groups. Treated mice received
daily eCF506 by oral gavage (40 mg/kg in ultrapure water, dissolved at
8 mg/mL) and control group mice received vehicle only. Mice were
imaged twice a week and the bioluminescence intensity of tumors in
the hind legs or jaw was quantified by M3 software. Mice were culled
when the tumor burden became too great.
Orthotopic breast cancer model
FVBorCD1nudemicewere anesthetizedby isofluraneand implanted
in the left fourth mammary fat pad with one million MetBo2 cells.
Tumors were allowed to grow until they reached around 50mm3 (FVB)
or 40 mm3 (CD1) in size (100 mm3 for the eCF506 versus dasatinib
study), after which, mice were randomly allocated into two groups. Mice
were treated with vehicle (3 mmol/L sodium citrate buffer pH 3.0) or
eCF506 (40 mg/kg, dissolved at 4 mg/mL in vehicle) once daily by oral
gavage (100 mL per 10 g mouse weight) for 3 days (PD study) or 28 days
(efficacy study). Of note, the use of citrate buffer instead of ultrapure
water allowed theproductionof a clear solutionof eCF506 just bymixing.
Tumor size was measured by caliper and mice weighed twice a week.
Mice were culled by cervical dislocation once tumor size reached 15mm
in diameter. After the initial treatment phase, surviving mice were
monitored until tumors relapsed. For the eCF506 versus dasatinib study,
treatment restarted once average tumor size reached approximately 0.3
to 0.4 cm3. Mouse that showed no tumor regrowth were monitored
(tumor volume and animal weight) during the duration of the study.
Mice were dosed 2 hours prior to culling by cervical dislocation, after
which, tumors were removed and fixed in neutral buffered formalin for
IHC and hematoxylin and eosin (H&E) staining. For the vehicle versus
dasatanib (20 mg/kg) versus eCF506 study (40 mg/kg), mice were
randomized into groups and treatment initiated as above once tumors
were detectable. Treatment was ceased at day 28, with treatment being
resumed for individual mice once increasing tumor growth was
observed. Once tumor endpoint (15 mm diameter) was reached, mice
were culled and tumors, spleens, and hearts of mice were dissected and
weights were recorded. Tissues were fixed in neutral buffered formalin
and paraffin embedded for IHC and H&E analysis.
Results
eCF506 targets the native inactive conformation of SRC
The majority of SRC kinase inhibitors bind to the catalytic domain
of SRC in its active conformation (38). To characterize the binding
mode of eCF506, we co-crystalized human SRC (kinase domain)
bound to eCF506 and determined the structure to 1.5 Å (for crystal-
lographic and refinement statistics see Supplementary Table S1, Sup-
plementary Materials and Methods). Remarkably, the structure
revealed that, contrary to our previous prediction (36), eCF506 binds
to the native inactive conformation of the SRC kinase (Fig. 1B andC).
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In this conformation, the C-helix is moved out and the K298-E313 salt
bridge (a hallmark of active kinases) is not formed (Fig. 1B; Supple-
mentary Figs. S1A and S1B, Supplementary Materials and Methods),
thereby switching kinase activity off.
In the native autoinhibited conformation of SRC, the SH2 and SH3
domains interact with the kinase domain and forma compact structure
that blocks macromolecular assemblies with other proteins. In con-
trast, these domains are released in the active state of SRC and the
protein adopts an open conformation that is free to interact with other
proteins (Fig. 2A), including FAK at focal adhesions (39). Biophysical
characterization of the hydrodynamic radius of full length SRC
(human SRC 84–536) in the absence (Apo) and presence of dasatinib
or eCF506 show that, whereas dasatinib induces opening of the SRC
structure, eCF506 maintains SRC in a more compact conformation,
similar to the Apo form (Supplementary Table S2, Supplementary
Materials andMethods). Consistent with these studies, a thermal shift
assay determined that eCF506 and dasatinib induce significant but
opposite effects on apparent melting temperature (Tm) of SRC com-
paredwithDMSO,with the former stabilizing the protein but the latter
destabilizing it (Fig. 2B).
eCF506 inhibits the formation of the SRC–FAK complex
The binding mode of eCF506, by which the compound locks SRC
into a closed inactive conformation, implies that upon eCF506 binding
the SH3 and SH2 domains will not be exposed to physically interact




















































































A, Proposed structural changes induced by eCF506 and dasatinib on human SRC protein. Created with BioRender. B, Thermal shift assay. MDA-MB-231 cells were
treated with eCF506 (0.3 mmol/L), dasatinib (0.3 mmol/L), or DMSO for 1 hour prior to heating, cell lysis and analysis of SRC byWestern blot anaysis. Band intensities
were normalized to the lowest temperature band for each condition. Error bars,SD (n¼ 3).  , P < 0.01;  , P < 0.001 (ANOVA). Bottom, representative Western
blots are shown. C, Coimmunoprecipitation (co-IP) study in MDA-MB-231 cells. Cells were treated with eCF506 (0.1 mmol/L), dasatinib (0.1 mmol/L), or DMSO for
6 hours and lysates incubated overnightwithmagnetic beads functionalizedwith anti-SRC IgG, followedbybead separation and analysis of SRC andFAKbyWestern
blot analysis. Band intensities were normalized to SRC and comparedwith DMSO values. Error bars,SD (n¼ 3).  , P < 0.05 (t test);  , P <0.001 (ANOVA). Bottom,
representative Western blots.
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of SRC to form complexes with its binding partner FAK, one of its
key substrates, should be reduced. This hypothesis infers in con-
sequence the opposite effect for classical kinase inhibitors that block
SRC in its active conformation, that is, the capacity of SRC to
assemble with other proteins should be enhanced. To test this, we
studied SRC–FAK binding in breast cancer MDA-MB-231 cells by
coimmunoprecipitation after treatment with eCF506 and clinical
kinase inhibitors dasatinib, bosutinib, and saracatinib. As seen
in Fig. 2C, dasatinib treatment increased by 3-fold the levels of
FAK in complex with SRC relative to the DMSO control, whereas
eCF506 decreased the recovery of FAK protein by 50%. Bosutinib
and saracatinib also increased binding of SRC to FAK (Supple-
mentary Fig. S2A, Supplementary Materials and Methods). Con-
sistent with these findings, coimmunoprecipitation studies with
magnetic beads functionalized with anti-FAK IgG led to equivalent
results, that is, dasatinib but not eCF506 increased SRC levels co-
precipitating with FAK relative to the untreated control (Supple-
mentary Fig. S2B, Supplementary Materials and Methods). These
findings fully agree with the proposed mode of inhibition of SRC by
eCF506.
eCF506 displays high selectivity across the kinome
Previous investigations (36) had only tested the activity of eCF506 in
a small panel of kinases (see Supplementary Table S3). To determine
the kinome-wide activity profile of eCF506, an enzymatic inhibition
screen was carried out with eCF506 at 1 mmol/L against 340 wild-type
protein kinases (n ¼ 2) by Reaction Biology Corp. With 0.1% of
remnant enzymatic activity, the highest degree of inhibition achieved
by eCF506 across the whole kinase panel was to the protein SRC. From
the 340 kinases tested, only 25 of them decreased their activity below
50% (see full list in Supplementary Table S4, Supplementary Materials
and Methods). This compares favorably with clinical SRC/ABL inhi-
bitors dasatinib and bosutinib, where the number of hit kinases is 51
and 85, respectively, using half of the concentration used for eCF506
(Supplementary Table S5, Supplementary Materials and Methods). In
agreement with previous results (36), ABL inhibition by eCF506 was
much lower than for dasatinib and bosutinib (56% ABL activity
remains after treatment, vs. 2.8% and 1.8%, respectively) and nine of
the identified hits are kinases from the SRC family, with levels of
remnant enzymatic activity between 5% and 0.1%. The rest of the hits
are members of the tyrosine kinase or tyrosine kinase-like family
branches. Outside the SRC family, the most potent hit found in the
screening was the nonreceptor tyrosine kinase BRK. However, deter-
mination of its IC50 value (see Supplementary Table S3) showed that
the potency of eCF506 against SRC (IC50 < 0.0005 mmol/L) is
significantly higher than against BRK (IC50 ¼ 0.0173 mmol/L), with
a 35-fold difference in activity between these targets.
eCF506 exhibits lower antiproliferative activity than SRC/ABL
inhibitors in BCR-ABL–positive leukemia cells
To study if the selectivity profile of eCF506 translate into weaker
phenotypic activity against ABL-driven cancer cells relative to classical
Figure 3.
A, Antiproliferative activities of eCF506, dasatinib, bosutinib, and saracatinib across 16 breast cancer cell lines. Calculated GI50 values are ranked by sensitivity to
eCF506. Error bars, SD (n ¼ 3). B, Cell-cycle analysis after treating MDA-MB-231 and MCF7 cells with eCF506 or dasatinib for 48 hours. Error bars,  SD (n ¼ 3).
Changes in G1 phase compared by one-way ANOVA (Dunnett correction for multiple comparison);  , P < 0.05;  , P < 0.0001; ns, nonsignificant. C, Representative
Western blots after treating MDA-MB-231 for 3 and 24 hours with eCF506, dasatinib, bosutinib, and saracatinib. Plots of normalized SRC-pY419 levels after each
treatment are shown at the bottom. Error bars, SD (n ¼ 3). D, Analysis of total and phosphorylated FAK from the RPPA study in MCF7 (top) and MDA-MB-231
(bottom) cells after 3 hours (left) and 24 hours (right) treatment with eCF506 and dasatinib at 0.3 to 300 nmol/L. Arrows, FAK-pY397.
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SRC/ABL inhibitors, we performed cell proliferation assays with three
BCR-ABL-positive chronic myeloid leukemia (CML) cell lines:
LAMA-84, KCL-22, and K-562. Inhibitors (eCF506, SRC/ABL inhi-
bitors dasatinib, bosutinib, and saracatinib, and ABL inhibitor ima-
tinib) were tested at a range of concentrations and their GI50 values
calculated (see Supplementary Fig. S3, Supplementary Materials and
Methods). Notably, results show that there is approximately 1,000-fold
difference in activity between dasatinib and eCF506 in the cell lines
tested, which correlates well with their difference in activity against
ABL in biochemical assays (see Supplementary Table S3).
eCF506 exhibits potent antiproliferative activity in ERþ and
triple-negative breast cancer cells
Encouraged by the distinct mechanism of action and increased
selectivity of eCF506, we screened eCF506 and clinical SRC/ABL
inhibitors against a panel of 16 breast cancer cell lines. As before, cell
viability was determined before and after adding the inhibitor to
calculate the concentration needed to inhibit proliferation by 50%
(GI50). The resulting GI50 values are ranked by cancer subtype and
sensitivity to eCF506 in Fig. 3A (dose–response curves are provided in
Supplementary Fig. S4, SupplementaryMaterials andMethods). Seven
cell lines treated with eCF506 displayed low GI50 values (0.015–0.22
mmol/L): the triple negative cell lines BT-549, MDA-MB-157, and
MDA-MB-231; the ERþ cell linesMCF7, ZR-75.1, and T-47D; and the
HER2þ cell line JIMT-1. The potency of eCF506 in these cell lines was
as high as or even higher (in ERþ cells) than that of dasatinib. On the
contrary, with the exception of JIMT-1 (cell line with acquired
resistance to anti-HER2 therapy; ref. 40), HER2þ breast cancer cell
lines showed low to negligible reduction of cell proliferation after
eCF506 treatment (GI50 > 1.8 mmol/L), which agrees with the expected
minor role played by SRC in HER2þ breast cancer cells before
becoming resistant to trastuzumab (41). Overall, eCF506 was the most
potent inhibitor against triple negative and ERþ cell lines showing
sensitivity (GI50 < 1 mmol/L) for SRC inhibitors, whereas displayed
lower inhibition of cell proliferation against HER2þ cell lines than any
other SRC inhibitor, further evidence of the high potency and selec-
tivity, respectively, of eCF506.
Analysis of the dose–response curves shows that eCF506 dis-
played anti-proliferative (not cytotoxic) effects at submicromolar
concentrations in all cell lines that exhibited sensitivity to treatment
(Supplementary Fig. S4, Supplementary Materials and Methods).
Cell-cycle assays in MDA-MB-231 and MCF7 cells confirmed that
both eCF506 and dasatinib induce arrest in the G1-phase (Fig. 3B).
In agreement with the cell viability assays, the cell-cycle arrest
mediated by eCF506 in MCF7 cells was greater than that of
dasatinib at the concentrations tested.
To test the selectivity of eCF506 on amodel of nonmalignant breast
epithelial cells, MCF10A cells were treated with eCF506 and dasatinib
at a range of concentrations (0.001–10 mmol/L) and cell viability
measured at day 5. As shown in Supplementary Fig. S5 (Supplemen-
tary Materials and Methods), eCF506 had minimal impact on cell
proliferation in this noncancerous cell line (EC50 > 10 mmol/L),
whereas dasatinib induced >50% reduction of cell viability at low
micromolar levels.
eCF506 inhibits cellular SRC activity more potently than clinical
SRC/ABL inhibitors
SRC undergoes autophosphorylation of its kinase domain at Y419
upon activation by upstream signaling events (8, 9), thus serving as a
direct readout of SRC kinase activity. As seen in Fig. 3C, eCF506 and
dasatinib led to almost complete inhibition of SRC phosphorylation at
0.1 mmol/L inMDA-MB-231 cells, whereas eCF506 displayed superior
potency at lower concentrations. Of note, eCF506 inducedmuchmore
potent inhibition of SRC-pY419 compared with dasatinib in MCF7,
T-47D, and ZR-75.1 cells (Supplementary Fig. S6, Supplementary
Materials and Methods), which correlates with the superior anti-
proliferative activity of eCF506 in ERþ cell lines. On the other hand,
both inhibitors led to complete SRC-pY419 inhibition in HER2þ
JIMT-1 cells at 0.1 mmol/L, suggesting that the superior antiprolifera-
tive activity of dasatinib versus eCF506 in this cell line (GI50 ¼ 0.048
and 0.222 mmol/L, respectively) is due to the effects of dasatinib on
pathways that do not depend on SRC. Bosutinib and saracatinib
displayed weaker inhibition of SRC autophosphorylation in all the
cell lines tested, requiring micromolar concentrations to induce
significant reduction of SRC-pY419 levels.
eCF506 indirectly reduces FAK autophosphorylation
To evaluate the overall impact of eCF506 and dasatinib upon
pathway signaling, we carried out a reverse phase protein array
(RPPA) screen to identify differences in total protein levels and
posttranslational modifications in MCF7 cells and MDA-MB-231
cells using the Zeptosens RPPA platform as described previously
(42). As expected, downregulation of SRC-pY419 and SRC phos-
phorylation sites on FAK (Y576/577, Y861, Y925), and compen-
satory upregulation of total SRC was observed with both com-
pounds, along with effects on a number of proteins involved in the
cell cycle and survival signaling pathways (see complete heat maps
and Western blot analysis of selected proteins in Supplementary
Figs. S7A–S7D, Supplementary Materials and Methods). The most
consistent and clear difference between dasatinib and eCF506
detected by RPPA was the differential phosphorylation of FAK-
Y397 (Fig. 3D). Dasatinib increased and eCF506 decreased phos-
phorylation of this residue in a concentration-dependent manner in
both cell lines. FAK-Y397 is autophosphorylated in response to
integrin and growth factor signaling, which creates a docking site
for SRC to bind via its SH2 domain, which in turn phosphorylates
multiple sites on FAK (Y576/577, Y861, Y925). To rule out the
direct inhibition of FAK kinase by eCF506 (note that, as shown
in Supplementary Table S3, eCF506 does not inhibit FAK at
1 mmol/L), we studied the effect of the inhibitor on FAK-pY397
in SYF cells, murine embryonic fibroblasts that are deficient for
SRC, YES, and FYN. Western blot analysis of lysates from SYF cells
treated with either eCF506 or dasatinib showed no concentration-
dependent changes in FAK-pY397 levels (Supplementary Fig. S8A,
Supplementary Materials and Methods), further evidence that these
inhibitors do not directly affect FAK kinase activity. Western blot
analysis of the negative regulatory site of SRC-pY530 after treat-
ment with eCF506 showed that the reduction of FAK-pY397 levels
correlated with a minor increase in the phosphorylation of
SRC-Y530, whereas the opposite results were observed with dasa-
tinib (Supplementary Fig. S8B, Supplementary Materials and Meth-
ods). These data suggest there is association between the SRC
structure and FAK-Y397 phosphorylation status.
Dasatinib, but not eCF506, triggers FAK translocation into the
nucleus
Coimmunoprecipitation and Western blot assays demonstrated
that SRC inhibitionmediated by dasatinib or eCF506 induces opposite
effects on SRC–FAK complex formation and FAK-pY397. The ques-
tion remains whether these contrasting activities lead to different
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effects on FAK function. Although FAK’s main role is to act as a
scaffold for focal adhesions at the cell membrane, FAK is also found in
the nucleus under cellular stress (43, 44), where it acts as a transcrip-
tional modulator. The effects of dasatinib and eCF506 on FAK
localization were then investigated by subcellular fractionation in
MDA-MB-231 cells (Supplementary Fig. S8C, Supplementary
Materials and Methods). Western blot analysis shows that SRC
kinase predominantly localizes to the perinuclear fraction, whereas
FAK is found in the cytoplasmic and perinuclear fractions. Notably,
dasatinib but not eCF506 increases the amount of nuclear
FAK, indicating that FAK shuttling from the cytoplasm to the
nucleus is triggered by dasatinib. These results were corroborated in
squamous cell carcinoma (SCC) cells (Supplementary Fig. S9A,
Supplementary Materials and Methods). Coimmunoprecipitation
studies of the nuclear fraction confirmed that FAK is bound to SRC
after dasatinib treatment (Supplementary Fig. S9B, Supplementary
Materials and Methods). The contrasting effects mediated by
dasatinib and eCF506 on the nuclear translocation of FAK are
important because the presence of FAK in the nucleus is associated
with gene expression changes that promote tumor evasion of
immune surveillance (45).
We then investigated a murine breast cancer cell model to produce
syngeneic grafts in mice with an intact immune system. MetBo2
cells are murine triple negative-like breast cancer cells derived from
bone homing cells following intracardiac inoculation of murine
Met1 cells (46, 47) and genetically modified to express firefly
luciferase. Western blot analysis of the MetBo2 cells (Supplemen-
tary Fig. S10A, Supplementary Materials and Methods) confirmed
high levels of Src-pY418 (mouse equivalent to human SRC-pY419).
Cell viability assays and immunoblotting showed that both dasa-
tinib and eCF506 elicit potent inhibition of MetBo2 proliferation
(Supplementary Fig. S10B, Supplementary Materials and Methods),
whereas eCF506 induces more potent Src-pY418 inhibition than
dasatinib at the same concentrations (Supplementary Fig. S10C,
Supplementary Materials and Methods). Subcellular fractionation
studies confirmed that dasatinib also triggers the translocation of
FAK into the nucleus in this cell line, but not eCF506 (Supple-
mentary Fig. S9, Supplementary Materials and Methods).
eCF506 shows excellent tolerability and potent
SRC inhibition in vivo
Toxicology studies were performed to inform on eCF506 safety and
experimental design before in vivo testing. Along with earlier studies
that established eCF506 is a weak inhibitor of CYP enzymes and hERG
channel activity (36), a negative Ames test confirmed that eCF506 is
notmutagenic (Supplementary Fig. S11, SupplementaryMaterials and
Methods). Single-dose acute toxicity studies in mice and rats deter-
mined that eCF506’s MTD by oral administration was greater than
200 mg/kg in both species, regardless of the gender (see full results in
Supplementary Tables S6 and S7, Supplementary Figs. S12A and S12B
and S13A and S13B, Supplementary Materials and Methods), and
>400 mg/kg in female mice.
We then investigated eCF506 exposure after a single oral dose in
female CD1 nude mice (study performed by Evotec). Three mice per
group were dosed with 40 or 80 mg/kg of eCF506 and analyzed at 2, 8,

















































































































































































A–C, In vivoPD study of Src-pY418 inhibition. CD1 nude femalemice implantedwithMetBo2 cells (left fourthmammary fat pad; approximate tumor volume¼0.1 cm3)
were randomized in four groups and treated daily for 3 days (oral) with eCF506 at 10, 20, and 40 mg/kg or vehicle. A, Representative IHC images of tumor sections
immunostained using anti-Src-pY418 antibody (brown) and counterstained with hematoxylin (blue). B, Quantitative analysis of Src-pY418 positive cells from
the IHC images. Error bars, SD from n ¼ 3.  , P < 0.01;  , P < 0.005 (ANOVA). C, Comparison of tumor size between groups at day 0 and 2. Error bars, SD
from n ¼ 3.  , P < 0.01 (ANOVA). D and E, In vivo study of breast tumor growth over time in immunocompetent FVB (D) and immunocompromised CD-1 nude
(E) mice during and posttreatment with vehicle or eCF506. Female mice implanted with MetBo2 cells (left fourth mammary fat pad; approximate tumor
volume ¼ 0.04–0.05 cm3) were randomized in two groups and treated daily for 28 days (oral) with eCF506 (40 mg/kg) or vehicle. After treatment
completion, animals were monitored until tumor relapse. F, Comparative analysis of tumor volumes at days 28 and 39 in FVB wild-type vs. CD1 nude mice
treated with eCF506. Error bars,  SD from n ¼ 5/group.  , P < 0.01 (t test). G–I, In vivo study of metastasis inhibition by eCF506 in syngeneic murine breast
cancer bone metastasis model. Female FVB mice injected with MetBo2 cells (left ventricle) were randomized in two groups 7 days after the injections and
treated daily for 28 days (oral) with eCF506 (40 mg/kg) or vehicle. G, Percentage BLI in left and right hind legs (two signals per animal) of vehicle- and
eCF506-treated mice relative to day 0. Animals were monitored for 63 days. H, Comparative analysis of % BLI between groups at day 7. Error bars,  SD from
n ¼ 8–10/group.  , P < 0.01 (t test). I, Bioluminescence tomography images of two representative mice from each group at day 7.
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levels between the doses (Supplementary Figs. S14A and S14B, Sup-
plementary Materials and Methods). A single oral dose of 40 mg/kg
achieved >0.2 mmol/L concentration of eCF506 in blood for 24 hours,
levels that in accordance with the MetBo2 cell studies (Supplementary
Fig. S10, SupplementaryMaterials andMethods) would be sufficient to
fully inhibit Src activity.
Next, we studied the optimal dose range required to achieve
effective inhibition of Src-pY418 in an orthotopic murine breast
cancer model. MetBo2 cells were injected into the mammary fat pad
of female mice (CD1 nude strain) and tumors allowed to grow up to
approximately 0.1 cm3. Mice were dosed daily for 3 days with
eCF506 (10, 20, or 40 mg/kg, in 3 mmol/L citrate buffer) or vehicle
(3 mmol/L citrate buffer) by oral gavage and culled 3 hours after the
last dose (n ¼ 3/group). Tumors were fixed, sections labeled for Src-
pY418 and stained with hematoxylin. As shown in Fig. 4A and B,
IHC analysis demonstrated significant reduction of Src-pY418 in
the allograft sections from mice treated with eCF506 at all doses
relative to the vehicle control, with the 40 mg/kg dose achieving
near complete inhibition. Of note, target inhibition correlated in a
dose-dependent manner with a reduction of tumor volume at day 2
of the treatment (Fig. 4C).
eCF506 shows enhanced antitumor activity in
immunocompetent cancer models
Next, we tested the in vivo antitumor activity of eCF506 in primary
breast cancer models in immunocompetent (FVB wild type) and
immunocompromised (CD1 nude) mice. MetBo2 cells were injected
into the mammary fat pad of female mice and, after 8 days, treated
them daily with vehicle (3 mmol/L citrate buffer) or 40 mg/kg eCF506
by oral gavage. Animals’ weight remained stable and comparable
between the treatment groups during the length of the study (Sup-
plementary Figs. S15A and S15B, Supplementary Materials and
Methods). Administration of eCF506 was stopped after 28 days and
tumor growth monitored in the absence of treatment until tumor
relapse. As shown in Fig. 4D and E, potent antitumor activity was
observed in all the mice treated with eCF506 from both immuno-
competent (Fig. 4D) and immunocompromised (Fig. 4E) strains
during the treatment phase, confirming the in vivo efficacy of
eCF506 and the sensitivity of MetBo2 allografts to Src inhibition.
Notably, major differences were observed during the posttreatment
phase. Residual tumors regrew rapidly in CD1 nude mice after
cessation of eCF506 treatment, undergoing >5-fold volume incre-
ment from days 28 to 39 (Fig. 4F). In contrast, tumor relapse was
delayed by more than 11 days in immunocompetent mice following
treatment cessation (Fig. 4D and F) and one mouse remained
tumor-free until the end of the study (53 days), suggesting involve-
ment of the immune system in the control of tumor growth during
the posttreatment phase.
We next tested eCF506 in a bone metastasis model established by
intracardiac injection of luciferase-expressing MetBo2 cells into the
left ventricle of FVB mice, and monitored by bioluminescence tomog-
raphy (Optima imager, Biospace). It is reported that metastatic breast
cancer cells that lodge in the bone marrow become addicted to SRC
signaling (47), what would make them highly susceptible to eCF506
treatment. The performance of this metastasis assay was also inspired
by the previously reported capacity of eCF506 to inhibit cell migra-
tion (36). Metastatic lesions were allowed to grow for 7 days until the
luminescence signals were clearly detected. Mice mainly developed
tumors in the hind legs (also in the jaw bones) and were randomized
into two treatment groups: vehicle (4 animals) or 40 mg/kg eCF506 (5
animals). The bioluminescence intensity (BLI) of tumors of each hind
leg was analyzed twice a week and plotted in Fig. 4G. Animals were
culled when the tumor burden became too great, which was achieved
for the vehicle group at days 7 to 21. Strong anticancer effect was
observed in all mice treated with eCF506 (Fig. 4H and I), inducing
regression of hind leg metastases in 4/5 mice during the treatment
phase. As in previous studies, monitoring of surviving mice (4) was
continued after the treatment period. The residual BLI in the hind legs
of these mice remained below detectable levels during the following
7 weeks (Fig. 4G). Although 2/4 mice developed metastatic lesions in
the thoracic cavity before the study termination (see imaging analysis
in Supplementary Figs. S16A and S16B, Supplementary Materials and
Methods), no bioluminescence signal was observed from hind legs or
bone jaw during the posttreatment phase, which indicates that bone
metastases were completely suppressed by the 28-day eCF506 treat-
ment in 4 of 5 mice treated.
Finally, we performed a head-to-head efficacy study between dasa-
tinib and eCF506 in the primary breast cancer model in immuno-
competent FVB mice (n ¼ 8/group). For consistency, the treatment
phase was run for 28 days. Dasatinib and eCF506 were dosed daily by
oral gavage at 20 and 40 mg/kg, respectively. Dasatinib’s dose of
20 mg/kg was chosen to achieve maximal therapeutic effect and good
tolerability, since higher repetitive doses can result in severe toxicity
and lethality (48–50). The weight of the animals wasmonitored during
the length of the study, which remained comparable between groups
(Supplementary Fig. S17, Supplementary Materials and Methods).
Potent antitumor response wasmediated by both inhibitors during the
treatment phase (Fig. 5A), displaying equivalent anticancer effect at
day 14 (Fig. 5B). However, whereas tumor growth was halted in the
eCF506-treated arm throughout the 28 days treatment period, a
significant increment in tumor volume was observed in the dasati-
nib-treated group by the end of the treatment period (day 28,
see Fig. 5B). Notably, the posttreatment phase revealed increasing
differences between the treatment groups, with rapid tumor relapses
occurring in the absence of treatment in the dasatinib-treated animals.
In contrast, tumor growth was significantly more delayed in the
mice treated with eCF506 (Fig. 5B). To test the response of the
relapsed MetBo2 allografts to inhibitors’ retreatment, we initiated a
second phase of treatment in those animals whose tumors reached an
approximate size of 0.3 cm3. The retreatment phase started at day 35
for the dasatinib-treated group. Following drug dosing, tumors under-
went partial regression, but started to regrow after a small number of
repeated dosing. The tumors of all the mice treated with dasatinib
evolved similarly throughout the different phases of the study and had
to be sacrificed at days 44 to 66. In contrast, the tumors of the
eCF506-treated group relapsed at different growth rates. Conse-
quently, the second phase of treatment was initiated on different
dates for each mouse: on day 39 (n ¼ 2), 43 (n ¼ 3), and 87 (n ¼ 1).
Notably, 2 of 8 eCF506-treated mice remained tumor-free until the
study endpoint (148 days) without the need of a second treatment
phase. Overall, the antitumor effect mediated by eCF506 in immu-
nocompetent mice was superior to that of dasatinib, resulting in
highly significant differences in survival (Fig. 5C). To investigate
potential reasons behind these variances, spleens, hearts, and
tumors were analyzed post-mortem (see Fig. 5D–F). The size of
the spleens was significantly smaller in the dasatinib-treated arm
compared with the vehicle and eCF506-treated groups (Fig. 5D).
Histologic analysis did not find differences between the spleens of
any of the groups (Supplementary Fig. S18, Supplementary Materi-
als and Methods), suggesting that the reduced spleens found in
the dasatinib-treated arm are not a sign of splenotoxicity but a
consequence of decreased spleen function, in agreement with
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toxicology studies performed in other animal models (50). Analysis
of tumor sections identified important differences between the
groups in peritumoral chronic inflammation and lymphocyte infil-
tration at the surrounding adipose-rich connective tissue (Fig. 5F;
Supplementary Fig. S19, Supplementary Materials and Methods).
Moderate to marked lymphocyte infiltration was seen in eCF506-
treated tumors, but only mild for the vehicle control and dasatinib-
treated tumors. IHC staining of tumor sections for CD3þ cells
indicated that eCF506 treatment leads to increased levels of tumor
infiltrating T cells compared with vehicle and dasatinib treatment
groups (Supplementary Fig. S20). However, large necrotic areas
(light brown) were also seen in the tumor samples treated by
eCF506, which may be in part responsible for the elevated lym-
phocyte infiltration. As seen in Fig. 5E, the hearts of the dasatinib-
treated arm were significantly heavier compared with the control
or eCF506 treatment. H&E analysis showed focal myocyte hydropic
change and variation in myocyte cell size only in animals
treated with dasatinib (Supplementary Figs. S21A and S21B,
Supplementary Materials and Methods). This is one of the expected
liabilities of ABL inhibition that limits dasatinib’s therapeutic
index (32–34, 50).
Because of the difficulty to compare immune cell changes from
long-term treated samples, we next performed a short-term study in
the immunocompetent orthotopicMetBo2 breast cancer model (n¼ 8
mice/group) by treating animals orally for 5 days with vehicle,
dasatinib (20 mg/kg) or eCF506 (40 mg/kg). Mice were culled at
endpoint and the weights of tumors, spleens, and hearts measured (see
Supplementary Fig. S22A, Supplementary Materials and Methods). In
agreement with prior studies, tumors were significantly reduced in the
animals treated with dasatinib or eCF506. Notably, although hearts
were unaffected, the weights of the spleens were significantly reduced
in the dasatinib-treated group relative to vehicle- and eCF506-treated
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A, In vivo study of tumor growth inhibition by eCF506 and dasatinib in immunocompetentmice. Female FVBmice implantedwithMetBo2 cells (left fourthmammary
fat pad; approximate tumor volume ¼ 0.1 cm3) were randomized in three groups and treated daily for 28 days (oral) with dasatinib (20 mg/kg; blue), eCF506
(40mg/kg; red), or vehicle (black). Tumors were measured twice per week. After day 28, animals were monitored until tumor relapse and a second treatment phase
initiatedwhen tumors reached avolumeof 0.3 cm3.B,Comparative analysis of tumor volumes of dasatinib- and eCF506-treated arms at day 14, 28, and 35. Error bars,
 SD from n ¼ 8/group.  , P < 0.01;  , P < 0.001 (t test). C, Kaplan–Meier survival plot showing deaths due to tumor size or sickness for each treatment group.
Statistical analysis by log-rank (Mantel–Cox) test. D and E, Comparative analysis of spleen (D) and heart weight (E) for vehicle-, dasatinib-, and eCF506-treated
groups at mouse endpoint. Error bars,SD from n¼ 8/group.  , P < 0.05 (ANOVA). Note that cured eCF506-treated mice (light red points), which did not need to
react to the tumor threat for 120 days, featured smaller spleens than the rest of the group. F, H&E-stained histology images of tumors after treatment with vehicle
(left), dasatinib (middle), and eCF506 (right). Black arrows point to the peritumoral chronic inflammatory infiltrates in surrounding adipose tissue to highlight the
differences between the groups. Scale bar, 250 mm.
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animals, indicating that the immunosuppressive effects of dasatinib
arise shortly after initiating the treatment. Intriguingly, immunophe-
notyping of tumor samples (n ¼ 5/group) by flow cytometry
found no differences in T-, B-, and NK-cell abundance between
the treatment groups (Supplementary Figs. S22B and S22C,
Supplementary Materials and Methods), suggesting that lympho-
cytes are not directly affected by the treatments, at least after five
daily doses. Transcriptomic analysis was then performed with
the remaining tumor samples using the PanCancer Immune Pro-
filing panel in the NanoString nCounter platform. As shown in
Supplementary Fig. S23, expression levels of nine genes associated
with the M1 macrophage phenotype, including CD80, were found
differentially regulated in eCF506-treated tumors relative to vehi-
cle- and dasatinib-treated animals. The results from the short-term
study suggests that, rather than directly affecting lymphocytic cell
population, eCF506 treatment induces changes in the infiltration
number and/or reprogramming of myeloid cells. Of note, four M2
associated genes and two biomarkers of tumor-associated macro-
phages were also differentially regulated in the eCF506-treated arm.
Discussion
The inherent promiscuity of kinase inhibitors is a double-edged
sword that critically influences the therapeutic scope of this class of
drugs. Although selected polypharmacologic properties can improve
cancer treatment by, for example, blocking redundant signaling path-
ways and/or mediating additive/synergistic effects, pan-kinase inhi-
bition frequently results in dose-limiting adverse effects and narrow
therapeutic indexes (51).Moreover, off-target activities can potentially
counteract the on-target therapeutic benefit of the drug,making kinase
selectivity a desirable feature not only to promote clinical success, but
also to pharmacologically elucidate cause–effect relationships of nom-
inated targets. The kinase inhibitors approved or in clinical develop-
ment that target SRC activity are classic examples of promiscuous
inhibitors, targeting many kinases beyond SRC and its most closely
related family members. In fact, they all are dual SRC/ABL inhibitors
with additional off-target activities dependent on the inhibitor.
Here we show that eCF506 inhibits SRC more potently than any
other kinase and displays low to no inhibition of 315 kinases of 340
tested (including ABL). Remarkably, co-crystal structure analysis
reveals that eCF506 induces and stabilizes the native inactive con-
formation of the SRC kinase domain, where the C-helix is displaced
away from the active site and breaks the salt bridge between E313 in
the C-helix and the catalytic K298 (39, 52). The limited availability
of SRC inhibitors displaying this mode of binding combined with
the benefits of targeting inactive kinase conformations make this
both a remarkable and meaningful finding that allows us to inter-
pret the properties of eCF506. Binding to inactive forms of kinases
often increase selectivity resulting from highly divergent inactive
kinase structures. Imatinib, for example, targets the inactive con-
formation of the ABL kinase and shows high selectivity over SRC.
This is because imatinib targets an inactive ABL conformation
where the Asp side chain of the catalytic DFG motif flips from
pointing into the active site (DFG-in) to point away from the active
site (DFG-out), thereby switching its kinase activity off (53), a
feature rarely seen in SRC family kinases. In contrast, ABL is not
thought to natively use the C-helix-out conformation as an “off-
switch.” Hence the mode of binding of eCF506 is optimal for
inhibiting SRC but not ABL, providing a sound explanation for
this unique selectivity feature. Structurally speaking, the mode of
binding of eCF506 to SRC (DFG-in, C-helix-out) is analogous to
that of the dual HER2/EGFR inhibitor lapatinib on its targets (54).
Lapatinib does not inhibit SRC family members, while eCF506 does
not inhibit HER2 or EGFR (see Supplementary Table S1, Supple-
mentary Materials and Methods), which illustrates the selectivity
offered by this binding mode.
A second advantage of targeting inactive conformations of kinases is
that it can affect noncatalytic scaffolding functions, in that inactive
kinases are often excluded from functional complexes with binding
partners. We show that the inactive conformation of the SRC kinase
domain induced by eCF506 is relayed to the full-length protein,
keeping the protein in a compact conformation, likely as seen in the
autoinhibited SRC structure (55). In cells, we show that eCF506
reduces SRC binding to its partner FAK. Notably, we also found that
the SRC/ABL inhibitor dasatinib (known to bind SRC in its active
conformation; ref. 53) induces precisely the opposite effect. These
results provide convincing evidence that eCF506 and dasatinib
bind and promote different conformations in SRC and endorse
the re-classification of eCF506 into a new functional category: “total
SRC inhibitor,” which inhibits both SRC kinase activity and scaf-
folding functions.
Screening across a panel of 16 breast cancer cell lines shows that the
on-target potency and selectivity of eCF506 translate into high anti-
proliferative effects against triple negative and ERþ breast cancer cells,
by inhibition of the cell cycle. We also show that eCF506 inhibits SRC
kinase activity with greater potency than any other SRC/ABL inhibitor
in all the cell lines tested, requiring 0.03 to 0.1 mmol/L to achieve full
inhibition. Importantly, the antiproliferative potency of eCF506 in the
sensitive breast cancer cells correlated well with the observed inhibi-
tion of SRC-pY419, although the potential contribution of partly
inhibiting other targets (e.g., BRK) cannot be ruled out. In agreement
with the literature (41), our results indicate that SRC activity has a
minor role on the proliferation and survival of HER2-driven breast
cancer cell lines, but it can become a driver of resistance in the context
of HER2 inhibition.
A remarkable observation that further differentiates eCF506 from
other SRC inhibitors is its indirect effect on the autophosphorylation
site of FAK, Y397. Mirroring the effect mediated by FAK inhibitors,
eCF506 reduces the levels of FAK-pY397 relative to the untreated
control. In contrast, dasatinib treatment results in amarked increment
of FAK-Y397 phosphorylation. The changes induced on FAK-pY397
by each inhibitor inversely correlates with the effect on SRC-pY530,
the negative regulatory site of SRC. Given that neither eCF506 nor
dasatinib directly affect FAK activity, we propose that the driving force
behind the changes on FAK-pY397 are the opposing effects mediated
by these inhibitors on the formation of the SRC–FAK complex
(Fig. 2A and C). Phosphorylation and dephosphorylation of FAK is
a dynamic process required for the assembly and disassembly of focal
adhesions.When SRC is forced into a closed conformation by eCF506,
its SH2 domain is not available to bind to the FAK-pY397 docking site
and form the active complex with FAK. This in turn overexposes the
pY397 site of FAK to enzymatic dephosphorylation (56). In contrast,
dasatinib’s promotion of SRC–FAK binding protects this site from
dephosphorylation.
In agreement with our findings, Higuchi and colleagues have
recently reported that type I SRC inhibitors like dasatinib are allosteric
facilitators of SRC conformational activation, enhancing SRC–FAK
complex formation and increasing FAK autophosphorylation (57).
They also observed that a decrease of dasatinib concentration leads to
activation of SRC–FAK signaling and cautioned about the possibility
that type I SRC kinase inhibitors can evoke growth signals in vivowhen
the drug concentration decreases, thus accelerating cancer growth. The
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alternative mode of inhibiting SRC mediated by eCF506 would not
lead to such paradoxical activation, which may be a critical advantage
to its clinical use.
Another result that highlights the distinct molecular conse-
quences of targeting different conformations of SRC is the effect
in the translocation of FAK into the nucleus. We show that
dasatinib triggers the translocation of FAK into the nucleus and
that nuclear FAK is found in complex with SRC. On the contrary,
SRC but not FAK can be detected in the nuclear fraction of cells
treated with eCF506, indicating that the active conformation of SRC
is required to traffic FAK into the nucleus.
We show that eCF506 mediates very potent in vivo antitumor
activity in murine triple-negative breast cancer models, against
primary tumors and bone metastases, regardless of the mouse strain
used. Nonetheless, we also show in the primary breast cancer model
that significant differences emerge in the posttreatment period:
mice with an intact immune system are capable to control tumor
growth beyond the treatment phase (> 10 days), whereas tumor
relapse occurs in immunosuppressed mice as soon as the animals
are off treatment. Emulating the results of eCF506 in immunosup-
pressed mice, we show that dasatinib elicits a strong anticancer
effect in immunocompetent mice during the treatment phase, but
tumor growth accelerates immediately after halting the treatment.
The posttreatment antitumor effect observed in the eCF506-treated
arm (25% of mice remained tumor-free after the initial treatment
phase) along with the higher response of most mice to the
second treatment phase, resulted in significantly superior survival
of the animals treated with eCF506 relative to dasatinib. Post-
mortem analysis of the animals revealed smaller spleens in the
dasatinib-treated group than in those treated with vehicle or
eCF506. Notably, this effect was also observed in the short-term
study (five daily doses). Taking into consideration that normal
splenic histology was observed in all the treatment groups, dasa-
tinib’s effects are consistent with spleen hypoactivity (50). This
is relevant because a reduction of tumor-fighting effector cells
can affect the capacity of the adaptive immune system to respond
to the cancer threat (58, 59). This is also supported by the histologic
analysis of the tumors, which revealed a higher presence of peri-
tumoral lymphocytes and CD3þ cells in the eCF506-treated
mice compared with the dasatinib group and the vehicle control.
However, the results from the short-term study suggests that
macrophage reprogramming may be involved in the initiation
of the differentiating phenotypic effects observed by eCF506
treatment. The overall pro-immune effects of eCF506 may be
associated with its high selectivity over kinases that are targeted
by dasatinib, such as ABL or KIT (see Supplementary Table S3).
Although dasatinib has shown good tolerability in cancer
patients (34), its broad immunosuppressive effects [which have
been found to benefit CML patients by reducing regulatory T
cells (60), but it also results in the suppression of cytotoxic T-
cell function (50, 61) and myelosuppression (62)] is a potential
disadvantage to treat solid malignancies in immunocompetent
animals. Finally, we show that some of the animals of the dasati-
nib-treated group presented significant enlargement of the heart
and damaged cardiac muscle tissue. This adverse effect, which is
attributed to Abl inhibition (33, 34, 50), was not observed in the
eCF506-treated group, which agrees with the superior safety profile
of this selective inhibitor.
In conclusion, we report here a mode of inhibiting SRC that impairs
both catalytic and scaffolding functions by locking the protein in its
native inactive conformation.Molecular and phenotypic data in breast
cancer models, both in vitro and in vivo, demonstrate that this
inhibition mode confers therapeutic advantages compared with
classical type I inhibitors. Due to its selectivity and mechanism-
of-action, we anticipate that eCF506 will become a tool of choice to
assist in the elucidation and characterization of the role of SRC
function in different pathologies. Finally, based on its in vivo
potency and tolerability, we support the nomination of this total
SRC inhibitor as a first-in-class clinical candidate for the treatment
of SRC-associated disorders.
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